Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En fase 1/2-studie av PBI-410 i avanserte solide svulster

24. september 2026 oppdatert av: Biohaven Therapeutics Ltd.

En fase 1/2, først i menneskelig, doseeskalering og doseutvidelsesstudie av PBI-410 hos deltakere med avanserte solide svulster

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

Studieoversikt

Detaljert beskrivelse

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510, a Trop-2 directed antibody-drug conjugate (ADC), in participants with previously treated, advanced solid tumors. The study comprises 2 parts: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion. The Phase 1 will investigate the safety and tolerability of BHV-1510 given in monotherapy and given in combination with cemiplimab and identify one or more recommended doses for expansion (RDEs) and the maximum-tolerated dose (MTD) (if one exists). Once the RDE has been established, Phase 2 will open to investigate the preliminary efficacy of BHV-1510 in signal-finding expansion cohorts.

Studietype

Intervensjonell

Registrering (Antatt)

500

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • Site-113
      • La Jolla, California, Forente stater, 92093
        • Rekruttering
        • Site-112
      • Palo Alto, California, Forente stater, 94304
        • Rekruttering
        • Site-111
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20016
        • Rekruttering
        • Site-114
    • Florida
      • Miami, Florida, Forente stater, 33176
        • Rekruttering
        • Site-103
      • Orlando, Florida, Forente stater, 32827
        • Rekruttering
        • Site-105
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Site-115
    • Georgia
      • Augusta, Georgia, Forente stater, 30912
        • Rekruttering
        • Site-110
    • Michigan
      • Detroit, Michigan, Forente stater, 48201
        • Rekruttering
        • Site-109
    • Missouri
      • St Louis, Missouri, Forente stater, 63108
        • Fullført
        • Site-101
    • New York
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Site-117
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73117
        • Rekruttering
        • Site-116
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Rekruttering
        • Site-108
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Site-107
    • Texas
      • Dallas, Texas, Forente stater, 75231
        • Rekruttering
        • Site-104
    • Utah
      • West Valley City, Utah, Forente stater, 84119
        • Rekruttering
        • Site-106
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • Site-102

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  • Male or female participants aged ≥18 years.

  • Unresectable, incurable, locally advanced or metastatic epithelial-origin solid tumor that is refractory to standard therapies, or has no approved standard therapies, or no approved standard therapies at its current treatment stage. If applicable to the tumor type, participants must have received platinum-based chemotherapy, standard of care immunotherapy, and standard of care targeted therapies.

  • Measurable disease (per RECIST 1.1).

  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

  • Participants have adequate hematologic, renal, liver, and coagulation function as defined by the following (blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility):

    • Hemoglobin ≥9 g/dL
    • Absolute neutrophil count >1,500/mm3; participants with known Duffy null phenotype who have absolute neutrophil count ≥1,200/mm3 may be enrolled
    • Platelets >100,000/mm3
    • Creatinine clearance ≥50 mL/min measured or estimated using the Cockcroft-Gault formula; 24-hour urine collection is allowed, but not required.
    • Total bilirubin ≤1.5 × upper limit of normal (ULN); participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)
    • Alkaline phosphatase <2.5×ULN (or ≤5×ULN for participants with hepatic and/or bone metastases)
    • International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN
    • Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
  • Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.

BHV-1510 in Combination with specific inclusion criteria:

  • histologically or cytologically documented advanced (locally, recurrent, inoperable, cannot betreated with curative intent) or metastatic cancer including Endometrial Carcinoma that is confirmed as proficient mismatch repair (pMMR)
  • received ≤ 2 prior lines of systemic anti-cancer therapy and at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease.

Key Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Clinically significant intercurrent disease.
  • Has symptomatic brain metastases or has had any radiation or surgery for brain metastases within 4 weeks of C1D1.
  • Has clinically significant corneal disease.
  • Requires supplemental oxygen for daily activities.
  • Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.
  • Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on imaging at Screening.
  • Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone and visceral metastasis therapy. Any major surgical procedure within 6 weeks prior to C1D1.
  • History of severe hypersensitivity reactions to other monoclonal antibodies or either the drug substances or inactive ingredients of BHV-1510.
  • Has current or previously treated leptomeningeal carcinomatosis.
  • Use of OAP1B1 and OATP1B3 inhibitors within 14 days prior to starting trial.

BHV-1510 in Combination Specific Exclusion Criteria:

  • Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling.
  • Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
  • Prior allogeneic stem cell or solid organ transplantation.
  • Patients with history of myocarditis.
  • Presence of cardiovascular disease

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: BHV-1510 Monoterapi doseeskalering

BHV-1510 will be administered on Day 1 every 3 weeks

Andre navn:
  • GQ1010
  • PBI-410

BHV-1510 will be administered on Day 1 every 2 weeks

Andre navn:
  • GQ1010
  • PBI-410

BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks

Andre navn:
  • GQ1010
  • PBI-410
Eksperimentell: BHV-1510 i kombinasjon med Cemiplimab doseøkning

BHV-1510 will be administered on Day 1 every 3 weeks

Andre navn:
  • GQ1010
  • PBI-410

BHV-1510 will be administered on Day 1 every 2 weeks

Andre navn:
  • GQ1010
  • PBI-410

BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks

Andre navn:
  • GQ1010
  • PBI-410

cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks

cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 1: Number of patients with adverse events (AEs)
Tidsramme: Through study completion, estimated as an average of 47 months

Description: Incidence and severity of AEs, serious adverse events (SAEs) and dose limiting toxicities (DLTs). Severity of AEs will be assessed according to the NCI CTCAE v5.0. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

Through study completion, estimated as an average of 47 months
Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)
Tidsramme: Approximately 15 months

Based on tolerability and preliminary antitumor activity. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

Approximately 15 months
Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months

Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.

Through study completion, estimated as an average of 47 months
Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months

Incidence and severity of AEs, SAEs and DLTs. Severity of AEs will be assessed according to the NCI CTCAE v5.0

Through study completion, estimated as an average of 47 months
Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1

Through study completion, estimated as an average of 47 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Fase 1 og 2: Maksimal plasmakonsentrasjon (CMAX) av BHV-1510, total antistoff og nyttelast (BHC-0080269)
Tidsramme: Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Fase 1 og 2: Område under konsentrasjonen versus tidskurve fra enden av infusjon til den siste målbare konsentrasjonen (auclast) av BHV-1510, total antistoff og nyttelast
Tidsramme: Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Fase 1 og 2: Område under konsentrasjonen kontra tidskurve over doseringsintervallet (Auctau) til BHV-1510, totalt antistoff og nyttelast
Tidsramme: Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Fase 1 og 2: Eliminasjonshalveringstid (T1/2) av BHV-1510, totalt antistoff og nyttelast
Tidsramme: Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Fase 1 og 2: Travkonsentrasjon (CTOUGH) av BHV-1510, total antistoff og nyttelast
Tidsramme: Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Opptil 8 tidspunkter, men ikke overstiger, 22 dager i syklusene 1 og 3
Fase 2: Effekter av BHV-1510 monoterapi og nyttelast på QTC-intervallet ved bruk av Fridericias korreksjonsmetode (QTCF), og på andre EKG-parametere (hjertefrekvens [HR], PR og QRS-intervall)
Tidsramme: Omtrent 15 måneder
Omtrent 15 måneder
Fase 1 og 2: Areal under konsentrasjons-tid-kurven ekstrapolert til uendelig (AUCinf) for BHV-1510, totalt antistoff og nyttelast
Tidsramme: Opptil 8 tidspunkter, men ikke overstige 22 dager i syklus 1
Opptil 8 tidspunkter, men ikke overstige 22 dager i syklus 1
Fase 1 og 2: Total kroppsklarering (CL) etter IV-administrering eller tilsynelatende total kroppsklarering (CL/F) etter SC-administrering av BHV-1510 og totalt antistoff
Tidsramme: Opptil 8 tidspunkter, men ikke overstige, 22 dager i syklus 1 og 3
Opptil 8 tidspunkter, men ikke overstige, 22 dager i syklus 1 og 3
Fase 1 og 2: Prosentvis biotilgjengelighet (%F) etter subkutan administrering av BHV-1510 og totalt antistoff
Tidsramme: Opptil 8 tidspunkter, men ikke overstige, 22 dager i syklus 1 og 3
Opptil 8 tidspunkter, men ikke overstige, 22 dager i syklus 1 og 3
Fase 1 og 2: Distribusjonsvolum ved stabil tilstand (Vss) etter IV-administrering eller tilsynelatende distribusjonsvolum ved stabil tilstand (Vss/F) etter SC-administrering av BHV-1510 og totalt antistoff
Tidsramme: Opptil 8 tidspunkter, men ikke mer enn 22 dager i syklus 1 og 3
Opptil 8 tidspunkter, men ikke mer enn 22 dager i syklus 1 og 3
Phase 1: ORR
Tidsramme: Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

Through study completion, estimated as an average of 47 months
Phase 1: Duration of Response (DoR)
Tidsramme: Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

Through study completion, estimated as an average of 47 months
Phase 1 and 2: Immunogenicity of BHV-1510
Tidsramme: Through study completion, estimated as an average of 47 months

Incidence of ADA at baseline and post-treatment, including ADA titer

Through study completion, estimated as an average of 47 months
Phase 2: Disease control rate (DCR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1

Through study completion, estimated as an average of 47 months
Phase 2: Progression free survival (PFS) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months

Assessed by RECIST v 1.1

Through study completion, estimated as an average of 47 months
Phase 2: Overall survival (OS) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months

OS is defined as the time period from the start of administration to death due to any cause

Through study completion, estimated as an average of 47 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Chief Medical Officer, Biohaven Pharmaceuticals, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. april 2024

Primær fullføring (Antatt)

1. februar 2028

Studiet fullført (Antatt)

1. februar 2028

Datoer for studieregistrering

Først innsendt

22. april 2024

Først innsendt som oppfylte QC-kriteriene

22. april 2024

Først lagt ut (Faktiske)

25. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • BHV1510-101 (PBI-410-101)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere